| Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer MP Petrova, MI Eneva, JI Arabadjiev, NV Conev, EG Dimitrova, ... Bioscience trends 14 (1), 48-55, 2020 | 54 | 2020 |
| Successful treatment with docetaxel plus nintedanib in a patient with lung adenocarcinoma and pulmonary fibrosis: A case report and literature review T Zlatanova, J Arabadjiev, G Kirova-Nedyalkova, D Nikova Frontiers in Oncology 12, 907321, 2022 | 1 | 2022 |
| The prognostic role of markers of systemic inflammation in patients with metastatic lung cancer receiving immunotherapy: A comprehensive review of the literature T Zlatanova, J Arabadjiev Pharmacia 71, 1-7, 2024 | | 2024 |
| Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first‐line setting R Gencheva, M Petrova, P Kraleva, S Hadjidekova, M Radanova, ... Cancer Reports 7 (2), e1966, 2024 | | 2024 |
| Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 … M Manova, J Arabadjiev, R Mangaldzhiev, A Dudov, D Penchev, ... Biotechnology & Biotechnological Equipment 37 (1), 2268753, 2023 | | 2023 |
| Co-occurrence of lung adenocarcinoma and pulmonary fibrosis in a patient: A comprehensive case study and review of existing literature on the successful utilization of nintedanib. T Zlatanova, J Arabadjiev Pharmacia (0428-0296) 70 (4), 2023 | | 2023 |
| PI3KCA mutation prevalence and outcome among patients with metastatic breast cancer in Bulgaria treated with first-line endocrine therapy. R Gencheva, S Hadjidekova, M Petrova, D Krustev, P Kraleva, ... Journal of Clinical Oncology 41 (16_suppl), e13005-e13005, 2023 | | 2023 |
| SUPPLEMENTARY APPENDIX M Manova, J Arabadjiev, R Mangaldzhiev, A Dudov, D Penchev, ... Biotechnol Biotechnol Equip 37, 2023 | | 2023 |
| Markers of systemic inflammation and efficacy of immune therapy in patients with metastatic lung cancer. A literature review T Zlatanova, J Arabadjiev, A Zlatareva Scripta Scientifica Salutis Publicae 8 (1), 2022 | | 2022 |
| Metastatic hyperprogression after consolidation therapy with durvalumab in a patient with stage III NSCLC: a case study and review of the literature. T Zlatanova, J Arabadjiev, T Nenkina, K Botsolis Medical Review/Meditsinski Pregled 56 (4), 2020 | | 2020 |
| High neutrophil to lymphocyte ratio as a predictor for hyperprogressive disease in patients with metastatic non-small cell lung cancer treated with pembrolizumab as a second line. M Petrova, M Eneva, JI Arabadjiev, NV Conev, E Dimitrova, KD Koynov, ... Journal of Clinical Oncology 38 (15_suppl), e21546-e21546, 2020 | | 2020 |
| Predictive and Prognostic Value of Tumour-Infiltrating Lymphocytes in Women with Breast Cancer J Arabadjiev PQDT-Global, 2020 | | 2020 |
| HER2-позитивен рак на гърдата-нови възможности в адювантното и неоадювантното лечение на ранно и локално авансирало заболяване J Arabadjiev | | |
| Предимства при приложението на афатиниб като 1-ва и 2-ра линия на лечение за локално авансирал и метастатичен недребноклетъчен рак на белия дроб T Zlatanova, J Arabadjiev, S Mustafa | | |
| Съчетана лъчехимиотерапия при локално авансирал III стадий недребноклетъчен карцином на бял дроб–съвременни стандарти K Yordanov, J Arabadjiev | | |
| Пандемия от COVID-19 и онкологично болни пациенти N Tsonev, J Arabadjiev, E Dimitrova, I Donev | | |
